Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 9Lymphoma, Non-Hodgkin 7Recurrence 2Lymphoma 2Cytokine Release Syndrome 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Glioblastoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Craniopharyngioma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1Astrocytoma 1Advanced Liver Cancers 1

Interventions

Temozolomide 40Magnetic Resonance Spectroscopy 19Radiotherapy 18Specimen Handling 14Radiation 12Bevacizumab 11Lomustine 9pembrolizumab 6fludarabine 5Surgical Procedures, Operative 5atezolizumab 4Nivolumab 4Ipilimumab 4Cyclophosphamide 4Carboplatin 4Biopsy 4cemiplimab 3azeliragon 3Immunoglobulin G 3Disulfides 3Aminolevulinic Acid 3veliparib 2trametinib 2rocakinogene sifuplasmid 2poly ICLC 2olaparib 2lutetium Lu 177 dotatate 2durvalumab 2dabrafenib 2contrast agent BR1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × tocilizumab × 90 days × Clear all
NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
59 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡